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Aims/hypothesis The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify 
individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-
degree relatives (IA-2A+ FDRs) of type 1 diabetic patients.  
Methods Hyperglycaemic clamps were performed in 17 non-diabetic IA-2A+ FDRs aged 14 to 33 years and in 21 
matched healthy volunteers (HVs). Insulin and C-peptide responses were measured during the first (5-10 min) 
and second (120-150 min) release phase, and after glucagon injection (150-160 min). Clamp-induced C-peptide 
release was compared with C-peptide release during OGTT  
Results Seven (41%) FDRs developed diabetes 3-63 months after their initial clamp test. In all phases they had 
lower C-peptide responses than non-progressors (p<0.05) and HVs (p<0.002). All five FDRs with low first-
phase release also had low second-phase release and developed diabetes 3-21 months later. Two of seven FDRs 
with normal first-phase but low second-phase release developed diabetes after 34 and 63 months, respectively. 
None of the five FDRs with normal C-peptide responses in all test phases has developed diabetes so far (follow-
up 56 to 99 months). OGTT-induced C-peptide release also tended to be lower in progressors than in non-
progressors or HVs, but there was less overlap in results between progressors and the other groups using the 
clamp. 
Conclusions/interpretation Clamp-derived functional variables stratify risk of diabetes in IA-2A+ FDRs and may 
more consistently identify progressors than OGTT-derived variables. A low first-phase C-peptide response 
specifically predicts impending diabetes while a low second-phase response may reflect an earlier disease stage. 
Trial registration: ClinicalTrials.gov NCT00654121  
Funding: The insulin trial was financially supported by Novo Nordisk Pharma nv. 
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Prevention ; Type 1 diabetes 
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Abbreviations 
ΔCP30   Increase in C-peptide between 0 and 30 min during OGTT 
∆Glucose30  Increase in glucose between 0 and 30 min during OGTT 
∆CP30/∆glucose30  Incremental response for C-peptide during OGTT 
DI   Disposition index 
FDR   First-degree relative 
HV   Healthy volunteer 
GADA   Glutamate decarboxylase antibodies 
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IA-2A   Insulinoma-associated protein-2 antibodies 
IAA   Insulin autoantibodies 
ICA   Islet cell cytoplasmic antibodies 
IGT   Impaired glucose tolerance 
ISI   Insulin sensitivity index 
MMTT   Mixed-meal tolerance test 
P10   10th percentile 
 
INTRODUCTION 
In type 1 diabetic patients preservation of residual beta cell function reduces glycaemic excursions and hence the 
risk of severe hypoglycaemia and chronic complications of hyperglycaemia [1]. A short treatment with 
humanised monoclonal anti-CD3 antibodies preserves beta cell function in recent-onset type 1 diabetes [2, 3], 
particularly in individuals with residual beta cell function ≥25% of controls [3]. This opens perspectives for 
immunomodulatory interventions in the late preclinical phase where beta cell function is likely to be even better 
preserved [4] and where anti-CD3 antibodies have also shown efficacy in animal models [5]. A trial in humans 
requires the identification of individuals with a beta cell mass that is sufficiently intact to expect efficacy, yet 
sufficiently reduced to warrant exposure to a possibly harmful medication. We wanted to investigate whether 
hyperglycaemic clamps [6, 7] can be used in this respect. An advantage of the clamp is that insulin release is not 
limited to the first phase, but is also quantified after prolonged glycaemic stimulation followed by a glucagon 
bolus. It was already instrumental in monitoring residual beta cell function in recent-onset type 1 diabetic 
patients and in recipients of a beta cell graft [3, 8]. In a secondary prevention trial with prophylactic insulin 
injections [9] we performed hyperglycaemic clamp tests and OGTTs at baseline in first-degree relatives (FDRs) 
of type 1 diabetic patients at high risk for developing diabetes within 5 years on the basis of insulinoma-
associated protein-2 antibody (IA-2A) positivity [10-13] and in a group of matched healthy volunteers (HVs). 
The specific aims were to investigate whether: (1) during the various test phases insulin and C-peptide responses 
differed between IA-2A-positive FDRs and HVs; (2) hormone release during glucose clamps could stratify 
diabetes risk in antibody-positive FDRs and provide more information on clinical outcome than release after 
acute glycaemic stimulation alone; (3) clamp-derived hormonal variables may better discriminate between rapid 
and slow progressors to diabetes than OGTT-derived variables. 
METHODS 
Participants 
High-risk first-degree relatives Hyperglycaemic clamps were performed in non-diabetic FDRs (nine siblings and 
eight offspring) of type 1 diabetic patients recruited by the Belgian Diabetes Registry (BDR). They did not differ 
in age, BMI and sex ratio from the HVs (Table 1) and were at high risk of the disease (about 50% within 5 
years), based on positivity for IA-2A in absence of protective HLA DQA1*-DQB1*genotypes [9-11, 14]. All but 
one tested positive for two or three other diabetes-associated autoantibodies. All FDRs were enrolled in an 
intervention study aiming at prevention of type 1 diabetes by prophylactic subcutaneous administration of low 
dose (0.05 U/kg twice a day) human regular insulin (Actrapid, Novo Nordisk, Brussels, Belgium) [9] (Fig. 1). 
The relatives and—in the case of minors—also their parents signed informed consent forms approved by the 
Ethics Committees of the BDR and of the four participating universities. The study was conducted in accordance 
with the guidelines in the Declaration of Helsinki as revised in 2000 (www/wma.net/e/policy/b3.htm, accessed 6 
June 2008). 
 
Table  1   General  characteristics  of IA-2A-positive relatives  and healthy volunteers 
Characteristics High-risk relatives Healthy volunteers 
n 17 21 
Age, years 21 (17-26) 23 (20-26) 
Family history of diabetes Yes No 
Male-to-female ratio (n/n) 10/7 9/12 
BMI (kg/m2) 23 (20-26) 22 (20-24) 
Basal glycaemia (mmol/l) 4.7 (4.3-5.0) 4.5 (4.4-4.8) 
Prevalence of diabetes antibodies, n/n (%)   
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IA-2A 17/17 (100)† 0/21 (0) 
ICA 16/17 (94)† 0/21 (0) 
GADA 16/17 (94)† 0/21 (0) 
IAA 6/17 (35)‡ 0/21 (0) 
GADA and/or IAA 16/17 (94)† 0/21 (0) 
HLA- DQ2/DQ8 genotype, n/n (%) 3/17 (17) 0/17 (0) 
Normal basal glycaemia at entry, n/n (%) 17/17 (100) 21/21 (100) 
Normal OGTT at entry, n/n (%) 14/17 (82) 15/15 (100) 
Development of diabetes, n/n (%) 7/17 (41)§ 0/21 (0) 
Data are median (interquartile range), n/n or n/n (%) † p<0.005, ‡ p<0.004, § p=0.002 vs healthy volunteers 
 
Fig. 1 Diabetes-free survival (%) in IA-2A-positive relatives stratified according to C-peptide response (AUC) 
during various phases of the hyperglycaemic clamp test at entry, a First-phase C-peptide response <P10 (n=5, 
dotted line). b First-phase C-peptide response >P10 and second-phase C-peptide response <P10 (n=7, dashed 
line), c First-phase C-peptide response >P10 and second-phase C-peptide response >P10 (n=5, solid line). The 




At entry, glucose tolerance was assessed by a 75 g oral glucose tolerance test (OGTT) [15]. One week later a 
hyperglycaemic clamp was performed in the FDRs and low-dose prophylactic insulin treatment was initiated for 
36 months [9]. Relatives were prospectively followed (median [range]: 64[3-99] months) for glucose tolerance 
and diabetes onset (OGTT after 3, 9, 15, 18, 21, 27, 30, 33, 36, 42 and 48 months; glucose self-monitoring) and 
for beta cell function (hyperglycaemic clamp after 6, 12, 24, 36 and 48 months). At diagnosis, patients were 
shifted to intensified insulin treatment and excluded from the trial. 
Healthy volunteers Hyperglycaemic clamps were performed three times with 1-3 week intervals in 21 HVs aged 
16-34 years. None of them took medications or had a family history of type 1 diabetes, or an FDR with type 2 
diabetes. All had normal BMI, tested negative for diabetes-associated antibodies (against islet cell cytoplasm 
[ICA], glutamate decarboxylase [GADA], IA-2 antigen [IA-2A], insulin [IAA]) and had normal fasting 
glycaemia. Of the 21 HVs, 15 underwent an OGTT that proved normal 1 to 3 weeks prior to the first 
hyperglycaemic clamp. Seventeen participants were genetically tested; they all lacked the high-risk HLA 
DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201(DQ2/DQ8) genotype (Table 1). 
Hyperglycaemic clamps 
All participants maintained their normal diet and physical activities during the days prior to the clamps. After an 
overnight fast a catheter was inserted into a right ante-cubital vein for blood sampling and into a left antecubital 
vein to infuse a concentrated glucose solution (1.1 mol/l; Baxter, Brussels, Belgium). At time 0 the plasma 
glucose concentration was acutely raised to reach the desired hyperglycaemic plateau of 10 mmol/l with a 
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priming dose of glucose during 14 min. The latter was calculated as a function of the body surface area and 
amounted to 48.3 mmol/m2 (time 0-5 min), 19.4 mmol/m2 (5-10 min), 11.7 mmol/m2 (10-14 min), and 10 
mmol/m2 (after 14 min). The hyperglycaemic plateau was maintained by adjusting the infusion rate according to 
bedside blood glucose levels measured every 5 min (HemoCue, Angelholm, Sweden). At time 150 min, 1 mg 
glucagon (Glucagen, Novo Nordisk, Bagsvaerd, Denmark) was injected via the left vein. The glucose infusion 
was stopped after 170 min. Blood samples for C-peptide, insulin and glucose were taken at time points -30, -15, 
0, 2.5, 5, 7.5, 10, 60, 120, 135, 150, 155, 160, 170, 190 and 210 min. The normal patterns of glycaemia and 
hormone secretion during the clamp are shown in the Electronic supplementary material [ESM] Fig. 1. 
Oral glucose tolerance tests 
Blood samples were collected before and 30, 60, 90 and 120 min after a 75 g glucose load and analysed for 
glucose and C-peptide. In three relatives only the fasting and the 120 min samples were available. 
Laboratory analyses 
Metabolic and hormonal variables Plasma glucose was measured on Vitros 950 IC (Ortho Clinical Diagnostics, 
Rochester, NY, USA), C-peptide by time-resolved fluo-roimmunoassay [16], proinsulin by ELISA [16] and 
insulin by a radioimmunometric assay (BI-INS-IRMA, Cisbio International, Gif-sur-Yvette, France). The 
proinsulin assay was considered to measure total proinsulin immunoreactive material [17]. As there is 100% 
cross-reactivity of proinsulin in the C-peptide assay, free C-peptide concentrations were obtained by subtracting 
the proinsulin concentration from the measured total C-peptide result. The interassay CVs at, respectively, low, 
median and high levels were 6.7% (mean 147 pmol/l), 5.2% (mean 530 pmol/l) and 4.9%  (mean   1773  pmol/l)  
for C-peptide,   11%  (mean 4.4 pmol/l), 7.2% (mean 28.7 pmol/l) and 12.5% (mean 111.4 pmol/l) for proinsulin, 
and 10.4% (mean 98.3 pmol/l), 6.0% (mean 353.5 pmol/l) and 4.8% (mean 901 pmol/l) for insulin. The cross-
reactivity of the proinsulin-like molecules in the insulin assay is negligible (manufacturer's specifications). 
Antibody assays and HLA-DQ genotyping ICA were determined by indirect immunofluorescence. IA-2A, 
GADA and IAA by liquid-phase radiobinding assays [18] and HLA-DQA1-DQB1 haplotypes by allele-specific 
oligotyping [14]. Cut-off values for antibody positivity represented the 99th percentile of antibody levels in 790 
non-diabetic controls [18]. In the 2007 Diagnostic Autoantibodies Standardization Program, diagnostic 
sensitivities adjusted for 95% specificity were, respectively, 63% for IAA, 94% for GADA, and 74% for IA-2A. 
cDNAs for the preparation of radiolabelled GAD and the intracellular domain of IA-2 were kindly donated by Ǻ. 
Lernmark (University of Washington, Seattle, WA, USA) and M. Christie (King's College, London, UK), 
respectively. 
Data analysis and statistical tests 
In the hyperglycaemic clamp tests basal hormone levels were calculated as the mean of measurements obtained 
at -30, -15 and 0 min. The release of C-peptide and insulin was calculated as the AUC using y=0 as baseline 
(first phase: between 5 and 10 min, AUC5-10 min; second phase: between 120 and 150 min, AUC120-150 min; after 
glucagon: between 150 and 160 min, AUC150-160 min) and expressed per min. A response below the 10th 
percentile (P10) of the control group was considered abnormal. Intra- and inter-individual CVs were determined 
according to Smith et al. [19] Insulin sensitivity was expressed as insulin sensitivity index (ISI) by dividing the 
amount of glucose metabolised between 120 and 150 min (M expressed as mmol kg-1 min-1) the average insulin 
concentration during the same period (I expressed as pmol/l), multiplied by 100. To correct for minor blood 
glucose fluctuations, M was calculated as the average glucose infusion rate between 120 and 150 min minus a 
'space correction' [6]. 
For OGTTs the AUC0-120 was calculated using y=0 as baseline and values were expressed per min. The increase 
in concentration between time 0 and 30 min was determined for glucose (∆glucose30) and C-peptide (∆CP30). 
The incremental response was defined as ∆CP30/∆glucose30 as previously described [20]. The disposition index 
(DI) [21] was computed by multiplying ISI from the clamp with the OGTT-derived AUC0-120 for C-peptide. 
Statistical tests were performed two-tailed using SPSS version 15.0 (SPSS, Chicago, IL, USA) and considered 
significant whenever p<0.05. Differences between groups were assessed by Mann-Whitney U or Kruskall-Wallis 
tests for continuous variables and by χ2 test, using Yates' correction or Fisher's exact test for categorical 
variables. Correlations between variables were assessed using the Spearman Rank test and differences between 
diabetes-free survival by Kaplan-Meier analysis and the logrank test. 
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RESULTS 
Progression to diabetes 
Seven of the 17 FDRs developed diabetes after a median (range) of 18 (3-62) months. In five progressors 
diagnosis was based on 2 h post-glucose-load glycaemia during OGTT, in one on glucose self-monitoring results 
and in one on clinical signs after his first clamp test; two of the predia-betic relatives had impaired glucose 
tolerance (IGT) at entry and developed diabetes 3 and 34 months later, respectively. Ten relatives remained non-
diabetic after a median (range) follow-up of 94 (55-99) months. Nine of them had a normal OGTT at baseline; 
one was glucose intolerant at entry but returned to normal later. Three non-progressors had transient IGT during 
follow-up. 
Hyperglycaemic clamp test in high-risk relatives 
Hormone release After having assessed the reproducibility of the clamp test by performing it three times in HVs 
(with 2-3 week intervals between tests) (ESM Table 1), we compared the hormone release of FDR and HV 
during their initial clamp test (Table 2). In all clamp phases the AUCs for C-peptide and insulin were lower in 
those who progressed to diabetes than in non-progressors or HVs. The results were similar if delta hormone 
responses were considered during the different phases (results not shown). HVs and high-risk FDRs did not 
differ significantly in their insulin-sensitivity index. Less glucose needed to be infused in progressors in order to 
clamp glycaemia at 10 mmol/l (Table 2). Overall there was a strong correlation between first- and second-phase 
AUC for C-peptide (r2=0.838, p<0.001) and between first-phase AUC and C-peptide after glucagon (r2=0.877, 
,p<0.001). 
Relation with clinical outcome Five relatives with first-phase C-peptide responses below the P10 of HVs 
developed diabetes 3 to 21 months after their initial clamp test (Fig. 1, group a). They also had low responses in 
the second and glucagon-stimulated phases and the most rapid progressor had IGT at entry. Seven relatives had a 
normal first-phase response but a low second-phase response (Fig. 1, group b); four of them had also a low 
glucagon-induced release.  Two relatives of group b  developed diabetes after, respectively, 34 and 64 months; 
the first had IGT at entry and low glucagon-induced release. The five relatives with normal first- and second-
phase responses had also normal post-glucagon responses and none of them developed diabetes during follow-up 
(range 64-99 months; Fig. 1, group c). The different groups in Fig. 1 did not differ in baseline characteristics 
(age, sex, BMI, HLA-DQ genotype, antibody levels or prevalence, and duration of IA-2A positivity). The 
amount of glucose infused during the clamp tended to be lower in group a than in groups b and c (not shown). 
Two relatives in group b and one in group c were transiently glucose intolerant. 
Comparison with C-peptide response during OGTT Like clamp-derived hormonal variables, OGTT-derived C-
peptide responses—in particular the incremental response during OGTT (∆CP30/∆glucose30), peak value, value at 
120 min and AUC0-120—tended to be lower in progressors than in non-progressors and HVs, while fasting 
glycaemia tended to be higher (Table 3). The three groups did not differ in disposition index calculated as the 
product of the clamp-derived ISI and the OGTT-derived AUC0-120 for C-peptide (Table 3). Clamp-derived first-
phase AUC for C-peptide was significantly correlated with C-peptide at 30 min (r2=0.71, p=0.004), AUC0-120 C-
peptide (r2=0.64, p=0.014) and peak C-peptide (r²=0.56, p=0.04) during OGTT, but not with ∆CP30/∆glucose30 
(r²=0.5,p=0.06). 
Both in the clamp test and OGTT, low C-peptide secretion was associated with later development of diabetes, 
but—particularly for rapid progressors—there was less overlap in results between progressors and non-
progressors or HVs using the clamp (Fig. 2). 
 
Table 2  Hyperglycaemic clamp-derived variables at baseline in healthy volunteers and high-risk relatives 
according to clinical outcome 
Variables Healthy volunteers 
(n=21) 





Basal     
Glucose (mmol/l) 4.6±0.1 4.5±0.1 4.8±0.2 0.211 
Insulin (pmol/l) 29±3 40±6 25±2 0.113 
C-peptide (pmol/l) 373±23 418±39 308±25 0.090 
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First phase: AUC5-10 min     
Glucose (mmol/l × min) 8.2±0.2 7.6±0.4 9.1±0.8 0.192 
Insulin (pmol/l × min) 134±13 153±35 58±15† 0.014 
C-peptide (pmol/l × min) 787±60 843±99 425±57†* 0.004 
Second phase: AUC120-150  min     
Glucose (mmol/l × min) 9.9±0.2 9.7±0.2 10.4±0.3 0.275 
Insulin (pmol/l × min) 338±38 454±145 137±28†* 0.010 
C-peptide (pmol/l × min) 2341±134 2269±266 1358±162†* 0.003 
After glucagon: AUC150-160 min     
Glucose (mmol/l × min) 10.8±0.3 11.2±0.3 10.2±0.4 0.258 
Insulin (pmol/l × min) 2012±142 2379±434 690±224†*** 0.002 
C-peptide (pmol/l × min) 4624±259 4618±563 2357±347†*** 0.002 
Insulin sensitivity index     
M/I120-150 mina 0.70±0.11 0.82±0.28 0.78±0.15 0.885 
Total amount of glucose infused     
Glucose infused (mmol/kg) 9.8±0.6 10.1±1.0 5.6±0.6†** 0.008 
Data are expressed as mean ± SE 
a Ratio of glucose metabolised between 120 and 150 min (expressed as mmol kg-1 min-1) and average insulin concentration between 120 and 
150 min (expressed as pmol/1) 
*p<0.05, **p<0.01, ***p<0.005 vs non-progressors; †p<0.002 vs healthy volunteers 
 
Fig. 2 Clamp-derived (panels a-c) and OGTT-derived (panels d-f) variables for C-peptide at baseline in healthy 
volunteers, relatives who progressed to diabetes (Pre-DM) and those who did not (No DM). a First-clamp-phase 
C-peptide AUC5-10 min. b Second-clamp-phase C-peptide AUC120-150 min· c Post-glucagon clamp phase C-peptide 
AUC150-160 min· d C-peptide at 30 min post-glucose load in OGTT. e Incremental C-peptide response during 
OGTT (∆CP30/∆glucose30). f C-peptide AUC0-120 min during OGTT. Because of some missing data the number of 
individuals in the various groups is slightly lower for OGTT-derived variables. In each panel the horizontal line 




Table 3  Oral glucose tolerance test at baseline in healthy volunteers and high-risk relatives according to 
clinical outcome 
Variables Healthy volunteers 
(n = 15) 





Basal     
Glucose (mmol/l) 4.5±0.1 4.3±0.1 4.9±0.2*† 0.039 
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C-peptide (pmol/l) 412±37 444±79 569±148 0.778 
Value at 30   min     
Glucose (mmol/l) 7.0±0.3 7.4±0.6 7.1±0.5 0.707 
C-peptide (pmol/l) 1,461±131 1,469±206 913±152 0.072 
Incremental response     
∆CP30/∆glucose30 430±80 535±216 218±44** 0.037 
Peak value     
Glucose (mmol/l) 7.3±0.4 7.4±0.5 7.9±0.7 0.824 
C-peptide (pmol/l) 2,309±149 2,000±242 1,515±106** 0.020 
Value at 120   min     
Glucose (mmol/l) 5.2±0.2 6.0±0.3 5.8±0.4 0.243 
C-peptide (pmol/l) 1,987±183 1,778±210 l,139±154†** 0.022 
AUC0-120 min     
Glucose (mmol/l × min) 5.9±0.3 6.3±0.4 6.8±0.4 0.188 
C-peptide (pmol/l × min) 1,700±116 1,481±175 1,144±87*** 0.019 
DIa 910±172 1066±314 775 ±148 0.984 
Data are expressed as mean ± SE 
aComputed as ISI obtained during clamp (see Table 2) × AUC CP0-120 min obtained during OGTT (expressed as pmol/l × min) 
*p<0.05, **p<0.01, ***p<0.005 vs healthy volunteers; † p<0.05 vs non-progressors 
 
DISCUSSION 
This study demonstrates for the first time that hyperglycaemic clamps can be used in antibody-positive FDRs of 
type 1 diabetic patients to consistently identify individuals close to clinical onset at a stage where fasting 
glycaemia or OGTT are still normal or inconsistent. In all clamp phases C-peptide and insulin responses were 
lower in individuals who progressed to diabetes than in those who did not and in HVs. A low first-phase C-
peptide release was invariably accompanied by low second-phase and post-glucagon responses, and consistently 
predicted impending diabetes. Moreover, two FDRs with low second-phase but normal first-phase responses 
developed hyperglycaemia after more than 2 years. Relatives with normal C-peptide responses in all phases have 
not progressed to diabetes so far. Clamp-derived C-peptide variables were significantly correlated with OGTT-
derived variables, but there was less overlap in results between progressors and non-progressors or HVs using 
the clamp. 
A strength of the study is that it has allowed comparison of the abilities of hormone release during the hyper-
glycaemic clamp and during OGTT to discriminate between progressors and non-progressors to diabetes in a 
group of well-characterised FDRs with close metabolic follow-up. An advantage of the clamp test is that—
unlike acute beta cell stimulation tests—it also allows study of second-phase and glucagon-stimulated hormone 
release after diagnosis of diabetes and thus it is possible to monitor beta cell function, if necessary, over a longer 
period [3, 8, 9]. Acute stimulation tests such as IVGTT or mixed-meal tolerance tests (MMTT) measure only 
hormonal release from the beta cell subpopulation that can be rapidly activated and some (e.g. MMTT) are 
influenced by gastrointestinal variables [22]. In contrast, prolonged glycaemic stimulation during glucose clamp 
tests is believed to recruit virtually all beta cells in a glucose-responsive state [23]. A limitation of our study is 
that all relatives received prophylactic insulin injections after the initial clamp test, but this intervention did not 
affect clinical outcome [9] nor the ability of clamp variables to predict it. The hyperglycaemic clamp is more 
laborious to perform than acute stimulation tests that have been widely used in diabetes prediction and 
prevention studies [20, 24-28], but compliance of relatives or patients was high in our hands [3, 8, 9]. The 
glucagon injection is the most burdening part of the test and does not seem to provide much additional 
information: one may therefore consider omitting it. The clamp procedure is too heavy for children under age 12, 
but performing only the first phase in this group may still allow comparison of C-peptide responses over a large 
age range. Our results also require confirmation in ongoing studies targeting larger groups of relatives with 
various risk levels according to their antibody status and followed for longer periods (K. Decochez, unpublished 
results). 
The present study shows for the first time that hormone release during prolonged beta cell stimulation can 
stratify diabetes risk in FDRs considered already at high risk based on their antibody status [10-13]. It illustrates 
that positivity for IA-2A and multiple autoantibody markers is, in itself, not indicative of a strikingly decreased 
beta cell function. Autoantibodies reflect an ongoing immune process but cannot be used as markers of residual 
beta cell function. IA-2A+ FDRs with a low first-phase C-peptide response during hyperglycaemic clamp should 
be considered for participation in immunointervention trials at the preclinical stage as they are at very high risk 
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for developing diabetes in the short term, but still have better preserved residual function (e.g. overall >50% of 
control values for second-phase C-peptide release in Table 2 vs 25% at onset of diabetes in [3]). On the other 
hand, IA-2A+ FDRs with normal C-peptide responses throughout the entire clamp procedure are unlikely to 
develop hyperglycaemia within 5 years and may not, therefore, be good candidates for immunointerventions. 
Our results suggest that at least in some prediabetic FDRs a low second-phase C-peptide release may precede the 
decrease in first-phase release and may thus reflect an earlier disease stage. Hyperglycaemic clamp tests may 
thus provide more information on clinical outcome than less cumbersome tests with only acute glycaemic 
stimulation. However, this requires confirmation in larger ongoing studies. The clamp test also allowed 
estimation of insulin sensitivity in FDRs and HVs, but in line with previous publications [29, 30] it failed to  
detect differences in biological measures of insulin sensitivity according to clinical outcome. 
Our results suggest that clamp-derived hormonal variables may discriminate better between rapid and slow 
progressors to diabetes than OGTT-derived variables. The clamp test may in this respect benefit from its good 
reproducibility (see ESM Table 1). In HVs the intra-individual CV for C-peptide AUC was lower than for 
insulin and approximated to 12%, which is in general better than values obtained with IVGTT or glucagon tests 
performed in duplicate in smaller groups [19, 31-34]. In line with an ADA workshop report, C-peptide also 
proved the most appropriate outcome measure in our hands [35, 36]. By performing clamp tests and OGTTs in 
parallel we were able to calculate disposition indices for most participants, but this variable could not 
discriminate between progressors and non-progressors in this study. 
In conclusion, clamp-derived hormonal variables stratify risk of diabetes in IA-2A-positive relatives. A low C-
peptide response during the first phase was invariably associated with rapid progression to diabetes. A decreased 
response during the second phase may provide an earlier and more sensitive indication for progression to 
diabetes, although larger studies are needed to confirm this. C-peptide release during the clamp may better 
discriminate between progressors and non-progressors to diabetes than OGTT-derived C-peptide values. In the 
light of previous results in individuals with recent-onset type 1 diabetes, relatives with IA-2A, multiple 
antibodies and decreased C-peptide release during clamp tests emerge as the most likely candidates to participate 
in immunointervention trials in the preclinical disease phase. 
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